Assessing the impact of different neutron RBEs on the all solid cancer radiation risks obtained from the Japanese A-bomb survivors data.
Int. J. Radiat. Biol. 99, 629-643 (2022)
PURPOSE: Development of a model characterizing risk variation with RBE to investigate how the incidence risk for all solid cancers combined varies with higher neutron RBEs and different organ dose types. MATERIAL AND METHODS: The model is based on RERF data with separate neutron and gamma dose information. RESULTS: For both additive and multiplicative linear excess risks per unit organ averaged dose, a reduction of 50% in the risk coefficient per weighted dose arises when a neutron RBE of 110 is used instead of 10. Considering risk per unit liver dose, this reduction occurs for an RBE of 130 and for risks per unit colon dose for an RBE of 190. The change in the shape of the dose response curve when using higher neutron RBEs is evaluated. The curvature changed and became significantly negative for males at an RBE of 140 for colon dose, 100 for liver dose and 80 for organ averaged dose. For females this is the case at an RBE of 110, 80 and 60, respectively. CONCLUSIONS: Uncertainties in neutron RBE values should be considered when radiation risks and the shape of dose responses are deduced from cancer risk data from the atomic bomb survivors.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Scopus
Cited By
Altmetric
Publication type
Article: Journal article
Document type
Scientific Article
Thesis type
Editors
Keywords
Relative Biological Effectiveness (rbe) ; Risk Assessment ; Atom Bomb Effects ; Cancer ; Epidemiology; Relative Biological Effectiveness; Dicentric Chromosomes; Human-lymphocytes; Life-span; Gamma; Mortality
Keywords plus
Language
english
Publication Year
2022
Prepublished in Year
0
HGF-reported in Year
2022
ISSN (print) / ISBN
0955-3002
e-ISSN
1362-3095
ISBN
Book Volume Title
Conference Title
Conference Date
Conference Location
Proceedings Title
Quellenangaben
Volume: 99,
Issue: 4,
Pages: 629-643
Article Number: ,
Supplement: ,
Series
Publisher
Informa Healthcare
Publishing Place
2-4 Park Square, Milton Park, Abingdon Or14 4rn, Oxon, England
Day of Oral Examination
0000-00-00
Advisor
Referee
Examiner
Topic
University
University place
Faculty
Publication date
0000-00-00
Application date
0000-00-00
Patent owner
Further owners
Application country
Patent priority
Reviewing status
Peer reviewed
POF-Topic(s)
30203 - Molecular Targets and Therapies
Research field(s)
Radiation Sciences
PSP Element(s)
G-501391-001
Grants
Swiss Federal Nuclear Energy Inspectorate (ENSI)
Copyright
Erfassungsdatum
2022-10-21